181 related articles for article (PubMed ID: 36920298)
21. Effectiveness and safety of statins on outcomes in patients with HIV infection: a systematic review and meta-analysis.
Vigny NN; Bonsu KO; Kadirvelu A
Sci Rep; 2022 Oct; 12(1):18121. PubMed ID: 36302940
[TBL] [Abstract][Full Text] [Related]
22. Safety of Statins and Nonstatins for Treatment of Dyslipidemia.
Newman CB
Endocrinol Metab Clin North Am; 2022 Sep; 51(3):655-679. PubMed ID: 35963634
[TBL] [Abstract][Full Text] [Related]
23. HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
Palmer SC; Navaneethan SD; Craig JC; Perkovic V; Johnson DW; Nigwekar SU; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD005019. PubMed ID: 24470059
[TBL] [Abstract][Full Text] [Related]
24. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice.
Finegold JA; Manisty CH; Goldacre B; Barron AJ; Francis DP
Eur J Prev Cardiol; 2014 Apr; 21(4):464-74. PubMed ID: 24623264
[TBL] [Abstract][Full Text] [Related]
25. The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs.
Herrett E; Williamson E; Brack K; Perkins A; Thayne A; Shakur-Still H; Roberts I; Prowse D; Beaumont D; Jamal Z; Goldacre B; van Staa T; MacDonald TM; Armitage J; Moore M; Hoffman M; Smeeth L
Health Technol Assess; 2021 Mar; 25(16):1-62. PubMed ID: 33709907
[TBL] [Abstract][Full Text] [Related]
26. Statin-associated muscle symptoms-Managing the highly intolerant.
Backes JM; Ruisinger JF; Gibson CA; Moriarty PM
J Clin Lipidol; 2017; 11(1):24-33. PubMed ID: 28391891
[TBL] [Abstract][Full Text] [Related]
27. The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes.
Chavarria V; Vian J; Pereira C; Data-Franco J; Fernandes BS; Berk M; Dodd S
Clin Ther; 2017 Mar; 39(3):477-486. PubMed ID: 28237673
[TBL] [Abstract][Full Text] [Related]
28. Preventing adverse events of chemotherapy by educating patients about the nocebo effect (RENNO study) - study protocol of a randomized controlled trial with gastrointestinal cancer patients.
Quidde J; Pan Y; Salm M; Hendi A; Nilsson S; Oechsle K; Stein A; Nestoriuc Y
BMC Cancer; 2018 Sep; 18(1):916. PubMed ID: 30249191
[TBL] [Abstract][Full Text] [Related]
29. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
[TBL] [Abstract][Full Text] [Related]
30. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses.
Cai T; Abel L; Langford O; Monaghan G; Aronson JK; Stevens RJ; Lay-Flurrie S; Koshiaris C; McManus RJ; Hobbs FDR; Sheppard JP
BMJ; 2021 Jul; 374():n1537. PubMed ID: 34261627
[TBL] [Abstract][Full Text] [Related]
31. The Challenge: Finding the Most Appropriate Statin and Dose for Each Patient.
Lillo JL
J Fam Pract; 2021 Jul; 70(6S):S53-S58. PubMed ID: 34432625
[TBL] [Abstract][Full Text] [Related]
32. When compliance is an issue-how to enhance statin adherence and address adverse effects.
Birtcher K
Curr Atheroscler Rep; 2015 Jan; 17(1):471. PubMed ID: 25410047
[TBL] [Abstract][Full Text] [Related]
33. Statin-associated adverse effects beyond muscle and liver toxicity.
Kiortsis DN; Filippatos TD; Mikhailidis DP; Elisaf MS; Liberopoulos EN
Atherosclerosis; 2007 Nov; 195(1):7-16. PubMed ID: 17094994
[TBL] [Abstract][Full Text] [Related]
34. Statins and myotoxicity: a therapeutic limitation.
Tiwari A; Bansal V; Chugh A; Mookhtiar K
Expert Opin Drug Saf; 2006 Sep; 5(5):651-66. PubMed ID: 16907655
[TBL] [Abstract][Full Text] [Related]
35. Muscle-related side-effects of statins: from mechanisms to evidence-based solutions.
Taylor BA; Thompson PD
Curr Opin Lipidol; 2015 Jun; 26(3):221-7. PubMed ID: 25943841
[TBL] [Abstract][Full Text] [Related]
36. Why Do I Get Side Effects? Personalized (N-of-1) Trials for Statin Intolerance and the Nocebo Effect.
Howard JP; Wood FA; Francis DP
Harv Data Sci Rev; 2022; 2022():. PubMed ID: 38344133
[TBL] [Abstract][Full Text] [Related]
37. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia.
Jacobson TA
Mayo Clin Proc; 2008 Jun; 83(6):687-700. PubMed ID: 18533086
[TBL] [Abstract][Full Text] [Related]
38. Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit.
Orringer CE; Blaha MJ; Stone NJ
J Clin Lipidol; 2021; 15(6):782-788. PubMed ID: 34688585
[TBL] [Abstract][Full Text] [Related]
39. Management of statin-intolerant patient.
Arca M; Pigna G; Favoccia C
Panminerva Med; 2012 Jun; 54(2):105-18. PubMed ID: 22525565
[TBL] [Abstract][Full Text] [Related]
40. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study.
Golomb BA; Kwon EK; Koperski S; Evans MA
Drug Saf; 2009; 32(8):649-61. PubMed ID: 19591530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
